Immune checkpoint inhibitor (ICI) and targeted BRAF/MEK inhibitor therapy (BRAF/MEKi) have dramatically improved the outcome of patients with metastatic melanoma [1] with ICIs being effective in many other cancer entities including non-small-cell lung cancer (NSCLC), urothelial cancer, squamous cell carcinoma and Merkel cell carcinoma. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.